Empyrean Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 6.00 Cr
as on 09-12-2024
- Revenue -98.62%
(FY 2022)
- Profit -198.67%
(FY 2022)
- Ebitda -1500.34%
(FY 2022)
- Net Worth -262.17%
(FY 2022)
- Total Assets 152.82%
(FY 2022)
About Empyrean Lifesciences
The Corporate was formerly known as Empyrean Lifescience Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹6.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Venkateswaran Nagraj and Sailesh Kumar serve as directors at the Company.
- CIN/LLPIN
U24232MH2014PTC367624
- Company No.
094543
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2014
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Empyrean Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sailesh Kumar  | Director | 01-Sep-2022 | Current |
| Venkateswaran Nagraj | Director | 31-Dec-2022 | Current |
Financial Performance and Corporate Structure Insights of Empyrean Lifesciences.
Empyrean Lifesciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 98.62% decrease. The company also saw a substantial fall in profitability, with a 198.67% decrease in profit. The company's net worth observed a substantial decline by a decrease of 262.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Empyrean Lifesciences?
In 2023, Empyrean Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Feb 2020 | ₹6.00 Cr | Satisfied |
How Many Employees Work at Empyrean Lifesciences?
Empyrean Lifesciences has a workforce of 32 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Empyrean Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Empyrean Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
